Harmony Biosciences Backs FY26 Revenue View of $1B-$1.04B
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2026
0mins
Harmony Biosciences backs FY26 revenue view $1B-$1.04B, consensus $1.02B
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HRMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HRMY
Wall Street analysts forecast HRMY stock price to rise
6 Analyst Rating
5 Buy
0 Hold
1 Sell
Moderate Buy
Current: 34.160
Low
32.00
Averages
43.83
High
55.00
Current: 34.160
Low
32.00
Averages
43.83
High
55.00
About HRMY
Harmony Biosciences Holdings, Inc. is a pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. WAKIX was developed for the treatment of excessive daytime sleepiness (EDS) in pediatric patients, six years and older, with narcolepsy. HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist. ZYN002 is an investigational drug product in development for the potential treatment of behavioral symptoms associated with Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q). It also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Avalo Therapeutics Appoints New Board Member
- New Board Appointment: Avalo Therapeutics has appointed Ron Philips to its Board of Directors, bringing over 30 years of experience in the biopharmaceutical industry, which is expected to significantly impact the company's strategic execution.
- Extensive Industry Background: Currently serving as executive chair of CREATE Medicines and on the boards of Harmony Biosciences and City Therapeutics, Philips was previously the CEO of Orbital Therapeutics, showcasing his deep expertise in biotechnology.
- Clinical Trial Advancement: Avalo plans to advance its investigational anti-IL-1ß monoclonal antibody Abdakibart (AVTX-009) into a registrational Phase 3 trial in the first half of 2027, marking a significant step in its drug development efforts.
- Stock Price Movement: Avalo closed at $17.83 on Tuesday, up 4.39%, but shares fell 1.51% in after-hours trading to $17.56, indicating cautious market sentiment regarding the new appointment.
See More
Paragon Biosciences Closes Sale of Emalex to Teva
- Significant Transaction Value: Paragon Biosciences successfully sold Emalex Biosciences to Teva Pharmaceuticals for a total of $700 million in cash and up to $200 million in commercial milestone payments, showcasing Paragon's strong capabilities and market recognition in the biotech sector.
- Innovative Drug Development: Emalex's Ecopipam, a first-in-class treatment for Tourette syndrome, demonstrated significant efficacy in a Phase 3 study published in JAMA Neurology, successfully reducing relapse time and improving tic symptoms, indicating its potential market value.
- Clinical Progress and Regulatory Path: Currently in clinical development, Ecopipam is expected to submit its New Drug Application in the second half of 2026, and if approved, it will be the first new treatment option for Tourette syndrome in over a decade, addressing urgent medical needs for patients.
- Company Mission and Vision: Paragon's founder, Jeff Aronin, emphasized that the company's mission is to translate scientific breakthroughs into medicines for patients, and it will continue to focus on unmet medical needs while advancing innovative drug development and market entry.
See More
Bridge City Capital Fully Exits Harmony Biosciences Holdings
- Complete Exit: Bridge City Capital fully exited its position in Harmony Biosciences Holdings during Q1, selling 237,103 shares for an estimated $7.77 million, indicating a reassessment of the company's future prospects.
- AUM Reduction: The transaction resulted in an $8.87 million decrease in Bridge City’s quarter-end position value in Harmony, highlighting the significant reduction of the company’s importance in the fund, which previously represented 2.6% of AUM.
- Poor Market Performance: As of May 12, 2026, Harmony's shares were priced at $30.15, down 15.4% over the past year, underperforming the S&P 500 by 42.07 percentage points, raising concerns about its growth potential.
- Investor Insight: Bridge City’s exit may reflect a valuation reassessment, prompting investors to monitor Harmony's long-term potential in the rare neurological disorder treatment market amidst changing market dynamics.
See More
Bridge City Capital Fully Exits Harmony Biosciences Holdings
- Complete Position Exit: Bridge City Capital sold all 237,103 shares of Harmony Biosciences in Q1, with an estimated transaction value of $7.77 million, indicating a significant loss of confidence that resulted in an $8.87 million decrease in the company's position value.
- AUM Reduction: This transaction led to a 2.15% reduction in Bridge City Capital's 13F reportable assets under management, reflecting a reassessment of their investment strategy, possibly due to concerns over market outlook.
- Industry Dynamics Impact: Harmony Biosciences focuses on treatments for rare neurological diseases, yet its recent poor market performance may have prompted institutional exits, suggesting a reevaluation of the company's future growth potential, which could affect its stock price and market confidence.
- Investor Caution: Before investing in Harmony Biosciences, investors should note that the company did not make it onto The Motley Fool Stock Advisor's list of top stocks, indicating a cautious market sentiment regarding its future performance.
See More
Harmony Biosciences Q1 2026 Earnings Call Insights
- Financial Performance: Harmony Biosciences reported net sales of $215.4 million in Q1 2026, reflecting a 17% year-over-year growth, and despite facing market access challenges, the company maintains its full-year revenue guidance of $1 billion to $1.04 billion, demonstrating confidence in future growth.
- Intellectual Property Protection: The company has successfully extended its pitolisant patent protection until March 2030 by settling with 6 of the 7 ANDA filers, ensuring market competitiveness and laying a foundation for future business development.
- R&D Progress: The NDA submission for pitolisant GR is expected this quarter with a target PDUFA date in Q1 2027, indicating ongoing advancements in drug development that could drive future revenue growth.
- Cash Flow Position: As of the end of Q1, Harmony Biosciences holds $870.5 million in cash and cash equivalents, with plans to deploy these funds into business development aimed at revenue contributions in the 2028 to 2032 timeframe, reflecting a proactive capital management strategy.
See More
Harmony Biosciences Q1 Earnings Miss Expectations
- Disappointing Earnings: Harmony Biosciences reported a Q1 GAAP EPS of $0.55, missing expectations by $0.14, indicating pressure on profitability that could undermine investor confidence.
- Lackluster Revenue Growth: The company generated $215.3 million in revenue for Q1, a 16.6% year-over-year increase, yet it fell short of expectations by $5.54 million, suggesting that market demand did not meet anticipated levels, potentially impacting future growth strategies.
- Rising Expenses: Total operating expenses reached $133.6 million in Q1, up 38% from $96.5 million in the same quarter of 2025, indicating significant cost pressures in operational management that could affect profit margins.
- Increased Administrative Costs: General and administrative expenses were $32.5 million in Q1, a 4% increase from $31.2 million in the same quarter last year, reflecting ongoing rising expenditures in management and operations that may impact overall financial health.
See More
Avalo Therapeutics Appoints New Board Member
- New Board Appointment: Avalo Therapeutics has appointed Ron Philips to its Board of Directors, bringing over 30 years of experience in the biopharmaceutical industry, which is expected to significantly impact the company's strategic execution.
- Extensive Industry Background: Currently serving as executive chair of CREATE Medicines and on the boards of Harmony Biosciences and City Therapeutics, Philips was previously the CEO of Orbital Therapeutics, showcasing his deep expertise in biotechnology.
- Clinical Trial Advancement: Avalo plans to advance its investigational anti-IL-1ß monoclonal antibody Abdakibart (AVTX-009) into a registrational Phase 3 trial in the first half of 2027, marking a significant step in its drug development efforts.
- Stock Price Movement: Avalo closed at $17.83 on Tuesday, up 4.39%, but shares fell 1.51% in after-hours trading to $17.56, indicating cautious market sentiment regarding the new appointment.
See More
Paragon Biosciences Closes Sale of Emalex to Teva
- Significant Transaction Value: Paragon Biosciences successfully sold Emalex Biosciences to Teva Pharmaceuticals for a total of $700 million in cash and up to $200 million in commercial milestone payments, showcasing Paragon's strong capabilities and market recognition in the biotech sector.
- Innovative Drug Development: Emalex's Ecopipam, a first-in-class treatment for Tourette syndrome, demonstrated significant efficacy in a Phase 3 study published in JAMA Neurology, successfully reducing relapse time and improving tic symptoms, indicating its potential market value.
- Clinical Progress and Regulatory Path: Currently in clinical development, Ecopipam is expected to submit its New Drug Application in the second half of 2026, and if approved, it will be the first new treatment option for Tourette syndrome in over a decade, addressing urgent medical needs for patients.
- Company Mission and Vision: Paragon's founder, Jeff Aronin, emphasized that the company's mission is to translate scientific breakthroughs into medicines for patients, and it will continue to focus on unmet medical needs while advancing innovative drug development and market entry.
See More
Bridge City Capital Fully Exits Harmony Biosciences Holdings
- Complete Exit: Bridge City Capital fully exited its position in Harmony Biosciences Holdings during Q1, selling 237,103 shares for an estimated $7.77 million, indicating a reassessment of the company's future prospects.
- AUM Reduction: The transaction resulted in an $8.87 million decrease in Bridge City’s quarter-end position value in Harmony, highlighting the significant reduction of the company’s importance in the fund, which previously represented 2.6% of AUM.
- Poor Market Performance: As of May 12, 2026, Harmony's shares were priced at $30.15, down 15.4% over the past year, underperforming the S&P 500 by 42.07 percentage points, raising concerns about its growth potential.
- Investor Insight: Bridge City’s exit may reflect a valuation reassessment, prompting investors to monitor Harmony's long-term potential in the rare neurological disorder treatment market amidst changing market dynamics.
See More
Bridge City Capital Fully Exits Harmony Biosciences Holdings
- Complete Position Exit: Bridge City Capital sold all 237,103 shares of Harmony Biosciences in Q1, with an estimated transaction value of $7.77 million, indicating a significant loss of confidence that resulted in an $8.87 million decrease in the company's position value.
- AUM Reduction: This transaction led to a 2.15% reduction in Bridge City Capital's 13F reportable assets under management, reflecting a reassessment of their investment strategy, possibly due to concerns over market outlook.
- Industry Dynamics Impact: Harmony Biosciences focuses on treatments for rare neurological diseases, yet its recent poor market performance may have prompted institutional exits, suggesting a reevaluation of the company's future growth potential, which could affect its stock price and market confidence.
- Investor Caution: Before investing in Harmony Biosciences, investors should note that the company did not make it onto The Motley Fool Stock Advisor's list of top stocks, indicating a cautious market sentiment regarding its future performance.
See More
Harmony Biosciences Q1 2026 Earnings Call Insights
- Financial Performance: Harmony Biosciences reported net sales of $215.4 million in Q1 2026, reflecting a 17% year-over-year growth, and despite facing market access challenges, the company maintains its full-year revenue guidance of $1 billion to $1.04 billion, demonstrating confidence in future growth.
- Intellectual Property Protection: The company has successfully extended its pitolisant patent protection until March 2030 by settling with 6 of the 7 ANDA filers, ensuring market competitiveness and laying a foundation for future business development.
- R&D Progress: The NDA submission for pitolisant GR is expected this quarter with a target PDUFA date in Q1 2027, indicating ongoing advancements in drug development that could drive future revenue growth.
- Cash Flow Position: As of the end of Q1, Harmony Biosciences holds $870.5 million in cash and cash equivalents, with plans to deploy these funds into business development aimed at revenue contributions in the 2028 to 2032 timeframe, reflecting a proactive capital management strategy.
See More
Harmony Biosciences Q1 Earnings Miss Expectations
- Disappointing Earnings: Harmony Biosciences reported a Q1 GAAP EPS of $0.55, missing expectations by $0.14, indicating pressure on profitability that could undermine investor confidence.
- Lackluster Revenue Growth: The company generated $215.3 million in revenue for Q1, a 16.6% year-over-year increase, yet it fell short of expectations by $5.54 million, suggesting that market demand did not meet anticipated levels, potentially impacting future growth strategies.
- Rising Expenses: Total operating expenses reached $133.6 million in Q1, up 38% from $96.5 million in the same quarter of 2025, indicating significant cost pressures in operational management that could affect profit margins.
- Increased Administrative Costs: General and administrative expenses were $32.5 million in Q1, a 4% increase from $31.2 million in the same quarter last year, reflecting ongoing rising expenditures in management and operations that may impact overall financial health.
See More
